SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001640455-22-000105
Filing Date
2022-12-20
Accepted
2022-12-20 07:21:01
Documents
12
Period of Report
2022-12-16
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K jnce-20221216.htm   iXBRL 8-K 35213
  Complete submission text file 0001640455-22-000105.txt   174450

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT jnce-20221216.xsd EX-101.SCH 1903
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT jnce-20221216_lab.xml EX-101.LAB 24831
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT jnce-20221216_pre.xml EX-101.PRE 13047
6 EXTRACTED XBRL INSTANCE DOCUMENT jnce-20221216_htm.xml XML 11259
Mailing Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 857-259-3840
Jounce Therapeutics, Inc. (Filer) CIK: 0001640455 (see all company filings)

IRS No.: 454870634 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37998 | Film No.: 221472833
SIC: 2836 Biological Products, (No Diagnostic Substances)